If an individual was to accept that LDX will likely achieve their short/medium term goals, then this analysis from an online article shows the upside potential available with the LDX share price.
According to the article:
- LDX has a price-to-sales (PS ratio) ratio of 1.3x
- half of all ASX med-tech companies have a PS ratio of 4.1x
- a PS ration of 15x are not unusual for med-tech stocks on the ASX
So, at a PS ratio of 1.3x,
LDX can triple in share price and still be below the average PS ratio for med-tech stocks on the ASX, and can
12-times its current value and still be in-line with the PS ration of many med-tech stocks on the ASX.
Current LDX share price is 3 cents per share multiplied by the above stated PS ratios:
$0.03 cents*3 = $0.09 cents per share
$0.03 cents*12 = $0.36 cents per share
IMO, LDX is significantly undervalued and has a lot of upside potential.
